HUP0203681A3 - Pharmaceutical compositions containing agonists specific for the peripheral cannabinoid receptor and their use - Google Patents

Pharmaceutical compositions containing agonists specific for the peripheral cannabinoid receptor and their use

Info

Publication number
HUP0203681A3
HUP0203681A3 HU0203681A HUP0203681A HUP0203681A3 HU P0203681 A3 HUP0203681 A3 HU P0203681A3 HU 0203681 A HU0203681 A HU 0203681A HU P0203681 A HUP0203681 A HU P0203681A HU P0203681 A3 HUP0203681 A3 HU P0203681A3
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
compositions containing
cannabinoid receptor
peripheral cannabinoid
agonists specific
Prior art date
Application number
HU0203681A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of HUP0203681A2 publication Critical patent/HUP0203681A2/hu
Publication of HUP0203681A3 publication Critical patent/HUP0203681A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
HU0203681A 1999-10-31 2000-10-30 Pharmaceutical compositions containing agonists specific for the peripheral cannabinoid receptor and their use HUP0203681A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL132661A IL132661A (en) 1999-10-31 1999-10-31 Agonists specific for peripheral cannabinoid receptors
PCT/US2000/029903 WO2001032169A1 (en) 1999-10-31 2000-10-30 Agonists specific for the peripheral cannabinoid receptor

Publications (2)

Publication Number Publication Date
HUP0203681A2 HUP0203681A2 (hu) 2003-04-28
HUP0203681A3 true HUP0203681A3 (en) 2003-05-28

Family

ID=11073405

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203681A HUP0203681A3 (en) 1999-10-31 2000-10-30 Pharmaceutical compositions containing agonists specific for the peripheral cannabinoid receptor and their use

Country Status (13)

Country Link
US (3) US6864291B1 (US06903137-20050607-C00002.png)
EP (1) EP1244440B1 (US06903137-20050607-C00002.png)
JP (1) JP4231906B2 (US06903137-20050607-C00002.png)
KR (1) KR100770695B1 (US06903137-20050607-C00002.png)
AT (1) ATE286389T1 (US06903137-20050607-C00002.png)
AU (1) AU778149B2 (US06903137-20050607-C00002.png)
CA (1) CA2385928A1 (US06903137-20050607-C00002.png)
DE (1) DE60017287T2 (US06903137-20050607-C00002.png)
HU (1) HUP0203681A3 (US06903137-20050607-C00002.png)
IL (2) IL132661A (US06903137-20050607-C00002.png)
NZ (1) NZ518054A (US06903137-20050607-C00002.png)
WO (1) WO2001032169A1 (US06903137-20050607-C00002.png)
ZA (1) ZA200202181B (US06903137-20050607-C00002.png)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342611B1 (en) * 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
ATE247097T1 (de) 1998-05-04 2003-08-15 Univ Connecticut Analgetische und immunomodulierende cannabinoiden
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
MXPA02005103A (es) 1999-10-18 2003-09-25 Alexipharma Inc Ligandos selectivos del receptor de canabinoide (cb2) perifericos.
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6943266B1 (en) * 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
JP2004532185A (ja) * 2001-01-26 2004-10-21 ユニバーシティ オブ コネチカット 新規なカンナビミメティックリガンド
US7173027B2 (en) * 2001-01-29 2007-02-06 University Of Connecticut Receptor selective cannabimimetic aminoalkylindoles
EP1414775B1 (en) * 2001-07-13 2012-12-19 The University of Connecticut Bicyclic cannabinoid
EP1448557A4 (en) 2001-10-26 2005-02-02 Univ Connecticut HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS
TW200407110A (en) 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
WO2003061699A1 (fr) * 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedes pour affections allergiques
WO2003063758A2 (en) * 2002-01-31 2003-08-07 Pharmos Corporation Bicyclic cb2 cannabinoid receptor ligands
IL150302A (en) * 2002-01-31 2008-07-08 Naim Menashe Bicyclic cb2 cannabinoid receptor ligands
JP2006511460A (ja) 2002-08-23 2006-04-06 ユニバーシティ オブ コネチカット 治療適応を持つケトカンナビノイド
EP1606019A1 (en) * 2003-03-07 2005-12-21 The University Court of The University of Aberdeen Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
JP2007501279A (ja) * 2003-05-20 2007-01-25 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデイション カンナビノイド誘導体、その製造方法、および使用
CA2571679A1 (en) * 2004-06-22 2005-12-29 Pharmos Limited Use of cb2 receptors agonists for the treatment of huntington's disease
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060638A1 (en) * 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
WO2007125048A1 (en) * 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US7763607B2 (en) 2006-04-27 2010-07-27 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
WO2008001369A1 (en) * 2006-06-27 2008-01-03 Pharmos Corporation Use of cb2 receptor agonists for promoting neurogenesis
US9763894B2 (en) * 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
GB0702862D0 (en) * 2007-02-14 2007-03-28 Univ Aberdeen Therapeutic compounds
WO2008107879A1 (en) * 2007-03-05 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel cannabidiol derivatives and their use as anti-inflammatory agents
EP2205240A1 (en) 2007-10-02 2010-07-14 Ariel-University Research And Development Company, Ltd. Endocannabinoids for enhancing growth and development in infants
US9193713B2 (en) 2007-10-12 2015-11-24 Abbvie Inc. Compounds as cannabinoid receptor ligands
WO2010041253A1 (en) 2008-10-06 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions comprising cb receptor agonists, uses thereof and methods for their preparation
WO2011009883A1 (en) 2009-07-23 2011-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Selective cb2 receptor agonists for use in the prevention or treatment of alcoholic liver disease
ITMI20122221A1 (it) 2012-12-21 2014-06-22 C4T S C A R L Nuovi composti del 2,3-diidro-4h-1,3-benzossazin-4-one, metodo per prepararli e forma farmaceutica che li comprende
US9486419B2 (en) 2013-04-17 2016-11-08 Ariel-University Research And Development Company CB2 receptor ligands for the treatment of psychiatric disorders
EP2992880A1 (en) * 2014-09-04 2016-03-09 Fundació Institut de Recerca de l'Hospital de la Santa Creu l Sant Pau Use of heme oxygenase 1 inducers and cannabinoid 2 receptor or delta-opioid receptor agonists in inflammatory pain
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2019030762A2 (en) 2017-08-09 2019-02-14 Stahl Veronica CANNABIS AND ITS DERIVATIVES FOR THE TREATMENT OF PAIN RELATED TO PAIN AND BONE REGENERATION ASSOCIATED WITH BONE DEFECTS IN THE JAW
WO2021080648A1 (en) * 2019-10-25 2021-04-29 Gelest Technologies, Inc. Silicon-based cannabidiol derivatives and compositions thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL55274A (en) 1978-08-02 1982-08-31 Yissum Res Dev Co 4-(2,6-dihydroxy-4-(dimethylheptyl)phenyl)substituted 2-pinen-10-ol and pinane derivatives,their preparation and pharmaceutical compositions comprising them
US5434295A (en) * 1994-02-07 1995-07-18 Yissum Research Development Company Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors

Also Published As

Publication number Publication date
AU1245801A (en) 2001-05-14
US7214716B2 (en) 2007-05-08
EP1244440A4 (en) 2003-05-14
HUP0203681A2 (hu) 2003-04-28
WO2001032169A1 (en) 2001-05-10
JP4231906B2 (ja) 2009-03-04
AU778149B2 (en) 2004-11-18
US20050165118A1 (en) 2005-07-28
JP2004505006A (ja) 2004-02-19
US6903137B2 (en) 2005-06-07
EP1244440A1 (en) 2002-10-02
ZA200202181B (en) 2003-05-28
EP1244440B1 (en) 2005-01-05
US20020173528A1 (en) 2002-11-21
KR100770695B1 (ko) 2007-10-29
IL148796A (en) 2008-11-26
DE60017287D1 (de) 2005-02-10
IL132661A0 (en) 2001-03-19
IL132661A (en) 2008-11-26
US6864291B1 (en) 2005-03-08
CA2385928A1 (en) 2001-05-10
ATE286389T1 (de) 2005-01-15
DE60017287T2 (de) 2005-12-08
KR20030008208A (ko) 2003-01-24
NZ518054A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
HUP0203681A3 (en) Pharmaceutical compositions containing agonists specific for the peripheral cannabinoid receptor and their use
HUP0203638A3 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them and their use
HUP0201545A2 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them
HUP0201243A2 (en) Glucocorticoid receptor modulators, pharmaceutical compositions containing them and their use
HUP0302969A3 (en) Npyy5 antagonists, pharmaceutical compositions containing them and their use
HUP0100101A3 (en) Prostaglandin agonists, pharmaceutical compositions comprising thereof and their use
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
HUP0400540A3 (en) 2-pyrazolin-5-one derivatives, their use and pharmaceutical compositions containing them
HUP0204081A3 (en) 4-pyrimidinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
IL202633A0 (en) Sulfonamide derivatives and pharmaceutical compositions containing the same
HUP0200709A3 (en) Triazole compounds with dopamine-d3-receptor affinity, pharmaceutical compositions containing them and their use
HUP0100266A3 (en) 1-amino-alkylcyclohexane nmda receptor antagonists, pharmaceutical compositions containing the compounds and their preparations
HUP0203556A3 (en) Pharmaceutical compositions containing oxcarbazepine and their use
HUP0200548A2 (hu) Gyógyszerészeti készítmények és alkalmazásuk
HUP0103884A3 (en) Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use
HUP0105003A3 (en) 2-oxy-4h-3,1-benzoxazin-4-one derivatives, their use and pharmaceutical compositions containing them
HUP0203194A3 (en) Phenylpiperazines, pharmaceutical compositions containing them and their use
HUP0203735A3 (en) 4-pyridinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use
IL133097A0 (en) Aroyl-piperazine derivatives pharmaceutical compositions containing the same and the use thereof
IL147214A0 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing the same
HUP9903758A3 (en) Benzoxazinone dopamine d4 receptor antagonists and pharmaceutical compositions containing the same
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
HUP0200055A3 (en) 16-hydroxyestrienes and pharmaceutical compositions containing the same
HUP0201910A3 (en) Novel aminobenzophenones, pharmaceutical compositions containing them and their use
HUP0203332A3 (en) Cyclothiocarbamate derivatives, their use as progesterone receptor modulators and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees